{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:32:06Z","timestamp":1793716326265,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00915-1","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:14:43Z","timestamp":1743750883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A retrospective research of adverse event reporting system events for voxelotor based on the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Ying","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"915_CR1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet (lond Engl). 2010;376:2018\u201331.","journal-title":"Lancet (lond Engl)"},{"key":"915_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-022-01237-z","volume":"15","author":"AM Brandow","year":"2022","unstructured":"Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022;15:20.","journal-title":"J Hematol Oncol"},{"key":"915_CR3","doi-asserted-by":"crossref","first-page":"a011783","DOI":"10.1101\/cshperspect.a011783","volume":"3","author":"GR Serjeant","year":"2013","unstructured":"Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3:a011783.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"915_CR4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.17312","volume":"194","author":"BS Pace","year":"2021","unstructured":"Pace BS, Starlard-Davenport A, Kutlar A. Sickle cell disease: Progress towards combination drug therapy. Br J Haematol. 2021;194:240\u201351.","journal-title":"Br J Haematol"},{"key":"915_CR5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317\u201322.","journal-title":"N Engl J Med"},{"key":"915_CR6","first-page":"347","volume":"57","author":"VL Tzounakas","year":"2018","unstructured":"Tzounakas VL, Valsami SI, Kriebardis AG, Papassideri IS, Seghatchian J, Antonelou MH. Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: current status, challenges and perspectives. Transfus Apher Sci: Off J World Apher Assoc: Off J Eur Soc Haemapheresis. 2018;57:347\u201357.","journal-title":"Transfus Apher Sci: Off J World Apher Assoc: Off J Eur Soc Haemapheresis"},{"key":"915_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-021-01781-w","volume":"16","author":"T Darshana","year":"2021","unstructured":"Darshana T, Rees D, Premawardhena A. Hydroxyurea and blood transfusion therapy for sickle cell disease in South Asia: inconsistent treatment of a neglected disease. Orphanet J Rare Dis. 2021;16:148.","journal-title":"Orphanet J Rare Dis"},{"key":"915_CR8","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2023-188616","volume":"142","author":"MO Achebe","year":"2023","unstructured":"Achebe MO, Hassab HM, Al-Kindi S, Brown C, Telfer P, Biemond BJ, et al. Over 4 years of safety and efficacy with voxelotor treatment for patients with sickle cell disease: updated results from an open-label extension of the phase 3 HOPE trial. Blood. 2023;142:2527.","journal-title":"Blood"},{"key":"915_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA. Voxelotor: First approval. Drugs. 2020;80:209\u201315.","journal-title":"Drugs"},{"key":"915_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","volume":"381","author":"E Vichinsky","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509\u201319.","journal-title":"N Engl J Med"},{"key":"915_CR11","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1002\/ajh.26101","volume":"96","author":"CP Minniti","year":"2021","unstructured":"Minniti CP, Knight-Madden J, Tonda M, Gray S, Lehrer-Graiwer J, Biemond BJ. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease. Am J Hematol. 2021;96:E126\u20138.","journal-title":"Am J Hematol"},{"key":"915_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2019-130802","volume":"134","author":"J Howard","year":"2019","unstructured":"Howard J, Vichinsky E, Knight-Madden J, Tonda M, Washington C, Tong B, et al. Correlation of voxelotor exposure with hemoglobin response and measures of hemolysis in patients from the HOPE study. Blood. 2019;134:1020.","journal-title":"Blood"},{"key":"915_CR13","doi-asserted-by":"crossref","unstructured":"Lemon N, Sterk E, Rech MA. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease. Am J Emerg Med. 2022;55:225.e1-225.e3.","DOI":"10.1016\/j.ajem.2021.12.031"},{"key":"915_CR14","first-page":"123","volume":"10","author":"M Migotsky","year":"2022","unstructured":"Migotsky M, Beestrum M, Badawy SM. Recent advances in sickle-cell disease therapies: A review of voxelotor, crizanlizumab, and L-glutamine. Pharm (Basel). 2022;10:123.","journal-title":"Pharm (Basel)"},{"key":"915_CR15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.18433\/jpps33020","volume":"25","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dong C, He X, Shu Y, Wu P, Zou J. Post-marketing safety of Vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting system. J Pharm Pharm Sci: Publ Can Soc Pharm Sci Soc Can Sci Pharm. 2022;25:377\u201390.","journal-title":"J Pharm Pharm Sci: Publ Can Soc Pharm Sci Soc Can Sci Pharm"},{"key":"915_CR16","doi-asserted-by":"crossref","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Gu L, Zhang Y, Zhou H, Wang Y, Xu Z-X. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system. Front Pharmacol. 2024;15:1290975.","journal-title":"Front Pharmacol"},{"key":"915_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40360-024-00821-y","volume":"25","author":"T Zou","year":"2024","unstructured":"Zou T, Li Z, Wang T, Deng S, Wang S, Hua Y. A real-world disproportionality analysis of the US food and drug administration (FDA) adverse event reporting system (FAERS) events for durvalumab. BMC Pharmacol Toxicol. 2024;25:97.","journal-title":"BMC Pharmacol Toxicol"},{"key":"915_CR18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","volume":"24","author":"S-P Zou","year":"2023","unstructured":"Zou S-P, Yang H-Y, Ouyang M-L, Cheng Q, Shi X, Sun M-H. A disproportionality analysis of adverse events associated to pertuzumab in the FDA adverse event reporting system (FAERS). BMC Pharmacol Toxicol. 2023;24:62.","journal-title":"BMC Pharmacol Toxicol"},{"key":"915_CR19","doi-asserted-by":"crossref","first-page":"1278442","DOI":"10.3389\/fphar.2024.1278442","volume":"15","author":"W He","year":"2024","unstructured":"He W, Wang Y, Chen K. A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam. Front Pharmacol. 2024;15:1278442.","journal-title":"Front Pharmacol"},{"key":"915_CR20","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, et al. Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Eclinicalmedicine. 2023;59:101967.","journal-title":"Eclinicalmedicine"},{"key":"915_CR21","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","volume":"8","author":"J Howard","year":"2021","unstructured":"Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): Long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8:e323\u201333.","journal-title":"Lancet Haematol"},{"key":"915_CR22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bjh.18813","volume":"202","author":"E Haroun","year":"2023","unstructured":"Haroun E, Dutta D, Lim SH. Effects of GBT1118, a voxelotor analog, on intestinal pathophysiology in sickle cell disease. Br J Haematol. 2023;202:184\u201394.","journal-title":"Br J Haematol"},{"key":"915_CR23","doi-asserted-by":"crossref","first-page":"H400","DOI":"10.1152\/ajpheart.00048.2021","volume":"321","author":"K Dufu","year":"2021","unstructured":"Dufu K, Williams AT, Muller CR, Walser CM, Lucas A, Eaker AM, et al. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice. Am J Physiol Heart Circ Physiol. 2021;321:H400\u201311.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"915_CR24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376:1561\u201373.","journal-title":"N Engl J Med"},{"key":"915_CR25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jth.13717","volume":"15","author":"E Sparkenbaugh","year":"2017","unstructured":"Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost: JTH. 2017;15:1307\u201316.","journal-title":"J Thromb Haemost: JTH"},{"key":"915_CR26","doi-asserted-by":"crossref","first-page":"1435220","DOI":"10.3389\/fphys.2024.1435220","volume":"15","author":"THR Silveira","year":"2024","unstructured":"Silveira THR, Calmasini FB, de Oliveira MG, Costa FF, Silva FH. Targeting Heme in sickle cell disease: New perspectives on priapism treatment. Front Physiol. 2024;15:1435220.","journal-title":"Front Physiol"},{"key":"915_CR27","doi-asserted-by":"crossref","unstructured":"Emmanuel A, Moussa A, Kesse-Adu R, Shabbir M. A contemporary review of the management strategies for sickle cell disease related ischaemic and stuttering priapism. Int J Impot Res. 2024:1\u20137.","DOI":"10.1038\/s41443-024-01008-z"},{"key":"915_CR28","unstructured":"Read ET. Mar 3 min. Priapism in sickle cell disease. Sickle-cell.com. https:\/\/sickle-cell.com\/complications\/priapism. Accessed 22 2025."},{"key":"915_CR29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.2021012070","volume":"138","author":"ER Henry","year":"2021","unstructured":"Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021;138:1172\u201381.","journal-title":"Blood"},{"key":"915_CR30","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.3390\/ijms24086999","volume":"24","author":"C Li","year":"2023","unstructured":"Li C, Zhao R, Yang H, Ren L. Construction of bone hypoxic microenvironment based on bone-on-a-chip platforms. Int J Mol Sci. 2023;24:6999.","journal-title":"Int J Mol Sci"},{"key":"915_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2013.09.001","volume":"27","author":"J Kanter","year":"2013","unstructured":"Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279\u201387.","journal-title":"Blood Rev"},{"key":"915_CR32","first-page":"1","volume":"49","author":"MS Thein","year":"2017","unstructured":"Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathol (Phila). 2017;49:1\u20139.","journal-title":"Pathol (Phila)"},{"key":"915_CR33","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","volume":"60","author":"D Hamideh","year":"2013","unstructured":"Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999\u20132009). Pediatr Blood Cancer. 2013;60:1482\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"915_CR34","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639\u201344.","journal-title":"N Engl J Med"},{"key":"915_CR35","first-page":"e7105","volume":"12","author":"SM AlDallal","year":"2020","unstructured":"AlDallal SM. Voxelotor: A ray of hope for sickle disease. Cureus. 2020;12:e7105.","journal-title":"Cureus"},{"key":"915_CR36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14656566.2018.1548610","volume":"20","author":"L Torres","year":"2019","unstructured":"Torres L, Conran N. Emerging pharmacotherapeutic approaches for the management of sickle cell disease. Expert Opin Pharmacother. 2019;20:173\u201386.","journal-title":"Expert Opin Pharmacother"},{"key":"915_CR37","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2018-08-868893","volume":"133","author":"J Howard","year":"2019","unstructured":"Howard J, Hemmaway CJ, Telfer P, Layton DM, Porter J, Awogbade M, et al. A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133:1865\u201375.","journal-title":"Blood"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00915-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:15:19Z","timestamp":1743750919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00915-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FAERS datasets are publicly accessible and anonymized, thus obviating the need for ethical approval in our current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}